Dietary lutein modulates growth and survival genes in prostate cancer cells

Journal of Medicinal Food

Volumn 18, Issue 2, 2015, Pages 173-181

  Rafi, Mohamed M ^a   Kanakasabai, Saravanan ^b   Gokarn, Sarita V ^a   Krueger, Eric G ^b   Bright, John J ^b,c  

^a RUTGERS UNIVERSITY   (United States)

^b METHODIST RESEARCH INSTITUTE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer prevention; Carotenoids; Lutein; PC 3 cells; Prostate cancer

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CIGLITAZONE; DOXORUBICIN; PACLITAXEL; PIOGLITAZONE; TEMOZOLOMIDE; XANTHOPHYLL; ANTINEOPLASTIC AGENT; CAROTENOID; ONCOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SURVIVAL-RELATED GENE PRODUCT, HUMAN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGONISTS; ANIMAL; BOVINE; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; FRUIT; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE; VEGETABLE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAROTENOIDS; CATTLE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; FRUIT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUTEIN; MALE; ONCOGENE PROTEINS; PPAR GAMMA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; VEGETABLES;

EID: 84922450766     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2014.0003     Document Type: Article

References (37)

1. Alves-Rodrigues A, Shao A: The science behind lutein. Toxicol Lett 2004;150:57-83.
2. Khachik F, Carvalho L, Bernstein PS, Muir GJ, Zhao DY, Katz NB: Chemistry, distribution, and metabolism of tomato carotenoids and their impact on human health. Exp Biol Med (Maywood) 2002;227:845-851.
3. Yeum KJ, Taylor A, Tang G, Russell RM: Measurement of carotenoids, retinoids, and tocopherols in human lenses. Invest Ophthalmol Vis Sci 1995;36:2756-2761.
4. Ribaya-Mercado JD, Blumberg JB: Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr 2004;23(6 Suppl):567S-587S.
5. Calvo MM: Lutein: a valuable ingredient of fruit and vegetables. Crit Rev Food Sci Nutr 2005;45:671-696.
6. Gunasekera RS, Sewgobind K, Desai S, et al.: Lycopene and lutein inhibit proliferation in rat prostate carcinoma cells. Nutr Cancer 2007;58:171-177.
7. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29.
8. Pal RP, Maitra NU,Mellon JK, KhanMA: Defining prostate cancer risk before prostate biopsy. Urol Oncol 2013;31:1408-1418.
9. Stearns ME, Wang M: Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 1992;52:3776-3781.
10. Tsakalozou E, Eckman AM, Bae Y: Combination effects of docetaxel and Doxorubicin in hormone-refractory prostate cancer cells. Biochem Res Int 2012;2012:832059.
11. Taverna P, Catapano CV, Citti L, Bonfanti M, D'Incalci M: Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas. Anticancer Drugs 1992;3: 401-405.
12. Rosen ED, Spiegelman BM: PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276:37731-37734.
13. Pestereva E, Kanakasabai S, Bright JJ: PPARgamma agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells. Br J Cancer 106:1702-1712.
14. Chearwae W, Bright JJ: PPARgamma agonists inhibit growth and expansion of CD133 + brain tumour stem cells. Br J Cancer 2008;99:2044-2053.
15. Mansour M, Schwartz D, Judd R, et al.: Thiazolidinediones/ PPARgamma agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol 38:537-546.
16. Xu Y, Iyengar S, Roberts RL, Shappell SB, Peehl DM: Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. J Cell Physiol 2003; 196:131-143.
17. Ban JO, Oh JH, Son SM, et al.: Troglitazone, a PPAR agonist, inhibits human prostate cancer cell growth through inactivation of NFkappaB via suppression of GSK-3beta expression. Cancer Biol Ther 12:288-296.
18. Lu QY, Arteaga JR, Zhang Q, Huerta S, Go VL, Heber D: Inhibition of prostate cancer cell growth by an avocado extract: role of lipid-soluble bioactive substances. J Nutr Biochem 2005;16:23-30.
19. Rafi MM, Shafaie Y: Dietary lutein modulates inducible nitric oxide synthase (iNOS) gene and protein expression in mouse macrophage cells (RAW 264.7). Mol Nutr Food Res 2007;51: 333-340.
20. Lee EH, Faulhaber D, Hanson KM, et al.: Dietary lutein reduces ultraviolet radiation-induced inflammation and immunosuppression. J Invest Dermatol 2004;122:510-517.
21. Rafi MM, Kanakasabai S, Reyes MD, Bright JJ: Lycopene modulates growth and survival associated genes in prostate cancer. J Nutr Biochem 2013;24:1724-1734.
22. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM: Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002;62: 2942-2950.
23. Sachdev D, Yee D: Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12.
24. Mitra A, Fisher C, Foster CS, et al.: Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008;98:502-507.
25. Dong JT: Prevalent mutations in prostate cancer. J Cell Biochem 2006;97:433-447.
26. Di Lorenzo G, Tortora G, D'Armiento FP, et al.: Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-3444.
27. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-1611.
28. Rocha-Lima CM, Soares HP, Raez LE, Singal R: EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
29. Borgono CA, Michael IP, Shaw JL, et al.: Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007;282:2405-2422.
30. Yousef GM, Stephan C, Scorilas A, et al.: Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 2003;56:287-292.
31. Haese A, de la Taille A, van Poppel H, et al.: Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54:1081-1088.
32. Marks LS, Bostwick DG: Prostate cancer specificity of PCA3 gene testing: examples from clinical practice. Rev Urol 2008; 10:175-181.
33. Whitman EJ, Groskopf J, Ali A, et al.: PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 2008;180:1975-1978; discussion 1978-1979.
34. Strock CJ, Park JI, Nakakura EK, et al.: Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006;66:7509-7515.
35. Agathanggelou A, Cooper WN, Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497-3508.
36. Li LC, Carroll PR, Dahiya R: Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005;97:103-115.
37. Meiers I, Shanks JH, Bostwick DG: Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology 2007;39:299-304.